Phase II study of epirubicin in advanced malignant melanoma
- PMID: 6595241
- DOI: 10.1007/BF00175383
Phase II study of epirubicin in advanced malignant melanoma
Abstract
Twenty patients with advanced malignant melanoma refractory to conventional chemotherapy, were entered into a Phase II study of epirubicin, one of the new doxorubicin analogues. The drug was given at a dose of 90 mg/m2 IV every 3 weeks. One partial response and three disease stabilizations were observed. Nausea and vomiting and alopecia were common. Mild to moderate leukopenia occurred in 6 patients. Three cases of reversible ST-T changes were recorded. The observed response rate of 5% with a 39.2% probability of a true response rate greater than or equal to 10%, does not suggest that epirubicin, in the dose and schedule chosen, is active in metastatic malignant melanoma.
References
MeSH terms
Substances
LinkOut - more resources
Medical